Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

With multiple entrants – including Stada’s Uzpruvo, Sandoz’s Pyzchiva, Celltrion’s Steqeyma, and Amgen’s Wezenla – clinicians may gravitate toward lower-cost alternatives, potentially ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

In a report released on March 17, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Sandoz Group Ltd (SDZXF – Research Report), ...

In a report released yesterday, Victoria Lambert from Berenberg Bank maintained a Hold rating on Sandoz Group Ltd (SDZXF – Research Report), with a price target of CHF41.00. The ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...